Search

Your search keyword '"M. Russcher"' showing total 9 results
Start Over Author "M. Russcher" Publication Year Range Last 50 years
9 results on '"M. Russcher"'

1. Incident energy dependence ofptcorrelations at relativistic energies

Author

J. Adams, M. M. Aggarwal, Z. Ahammed, J. Amonett, B. D. Anderson, D. Arkhipkin, G. S. Averichev, S. K. Badyal, Y. Bai, J. Balewski, O. Barannikova, L. S. Barnby, J. Baudot, S. Bekele, V. V. Belaga, A. Bellingeri-Laurikainen, R. Bellwied, J. Berger, B. I. Bezverkhny, S. Bharadwaj, A. Bhasin, A. K. Bhati, V. S. Bhatia, H. Bichsel, J. Bielcik, J. Bielcikova, A. Billmeier, L. C. Bland, C. O. Blyth, B. E. Bonner, M. Botje, A. Boucham, J. Bouchet, A. V. Brandin, A. Bravar, M. Bystersky, R. V. Cadman, X. Z. Cai, H. Caines, M. Calderón de la Barca Sánchez, J. Castillo, O. Catu, D. Cebra, Z. Chajecki, P. Chaloupka, S. Chattopadhyay, H. F. Chen, Y. Chen, J. Cheng, M. Cherney, A. Chikanian, W. Christie, J. P. Coffin, T. M. Cormier, J. G. Cramer, H. J. Crawford, D. Das, S. Das, M. Daugherity, M. M. de Moura, T. G. Dedovich, A. A. Derevschikov, L. Didenko, T. Dietel, S. M. Dogra, W. J. Dong, X. Dong, J. E. Draper, F. Du, A. K. Dubey, V. B. Dunin, J. C. Dunlop, M. R. Dutta Mazumdar, V. Eckardt, W. R. Edwards, L. G. Efimov, V. Emelianov, J. Engelage, G. Eppley, B. Erazmus, M. Estienne, P. Fachini, J. Faivre, R. Fatemi, J. Fedorisin, K. Filimonov, P. Filip, E. Finch, V. Fine, Y. Fisyak, J. Fu, C. A. Gagliardi, L. Gaillard, J. Gans, M. S. Ganti, F. Geurts, V. Ghazikhanian, P. Ghosh, J. E. Gonzalez, H. Gos, O. Grachov, O. Grebenyuk, D. Grosnick, S. M. Guertin, Y. Guo, A. Gupta, T. D. Gutierrez, T. J. Hallman, A. Hamed, D. Hardtke, J. W. Harris, M. Heinz, T. W. Henry, S. Hepplemann, B. Hippolyte, A. Hirsch, E. Hjort, G. W. Hoffmann, H. Z. Huang, S. L. Huang, E. W. Hughes, T. J. Humanic, G. Igo, A. Ishihara, P. Jacobs, W. W. Jacobs, M. Jedynak, H. Jiang, P. G. Jones, E. G. Judd, S. Kabana, K. Kang, M. Kaplan, D. Keane, A. Kechechyan, V. Yu. Khodyrev, J. Kiryluk, A. Kisiel, E. M. Kislov, J. Klay, S. R. Klein, D. D. Koetke, T. Kollegger, M. Kopytine, L. Kotchenda, K. L. Kowalik, M. Kramer, P. Kravtsov, V. I. Kravtsov, K. Krueger, C. Kuhn, A. I. Kulikov, A. Kumar, R. Kh. Kutuev, A. A. Kuznetsov, M. A. C. Lamont, J. M. Landgraf, S. Lange, F. Laue, J. Lauret, A. Lebedev, R. Lednicky, S. Lehocka, M. J. LeVine, C. Li, Q. Li, Y. Li, G. Lin, S. J. Lindenbaum, M. A. Lisa, F. Liu, H. Liu, L. Liu, Q. J. Liu, Z. Liu, T. Ljubicic, W. J. Llope, H. Long, R. S. Longacre, M. Lopez-Noriega, W. A. Love, Y. Lu, T. Ludlam, D. Lynn, G. L. Ma, J. G. Ma, Y. G. Ma, D. Magestro, S. Mahajan, D. P. Mahapatra, R. Majka, L. K. Mangotra, R. Manweiler, S. Margetis, C. Markert, L. Martin, J. N. Marx, H. S. Matis, Yu. A. Matulenko, C. J. McClain, T. S. McShane, F. Meissner, Yu. Melnick, A. Meschanin, M. L. Miller, N. G. Minaev, C. Mironov, A. Mischke, D. K. Mishra, J. Mitchell, B. Mohanty, L. Molnar, C. F. Moore, D. A. Morozov, M. G. Munhoz, B. K. Nandi, S. K. Nayak, T. K. Nayak, J. M. Nelson, P. K. Netrakanti, V. A. Nikitin, L. V. Nogach, S. B. Nurushev, G. Odyniec, A. Ogawa, V. Okorokov, M. Oldenburg, D. Olson, S. K. Pal, Y. Panebratsev, S. Y. Panitkin, A. I. Pavlinov, T. Pawlak, T. Peitzmann, V. Perevoztchikov, C. Perkins, W. Peryt, V. A. Petrov, S. C. Phatak, R. Picha, M. Planinic, J. Pluta, N. Porile, J. Porter, A. M. Poskanzer, M. Potekhin, E. Potrebenikova, B. V. K. S. Potukuchi, D. Prindle, C. Pruneau, J. Putschke, G. Rakness, R. Raniwala, S. Raniwala, O. Ravel, R. L. Ray, S. V. Razin, D. Reichhold, J. G. Reid, J. Reinnarth, G. Renault, F. Retiere, A. Ridiger, H. G. Ritter, J. B. Roberts, O. V. Rogachevskiy, J. L. Romero, A. Rose, C. Roy, L. Ruan, M. Russcher, R. Sahoo, I. Sakrejda, S. Salur, J. Sandweiss, M. Sarsour, I. Savin, P. S. Sazhin, J. Schambach, R. P. Scharenberg, N. Schmitz, K. Schweda, J. Seger, P. Seyboth, E. Shahaliev, M. Shao, W. Shao, M. Sharma, W. Q. Shen, K. E. Shestermanov, S. S. Shimanskiy, E. Sichtermann, F. Simon, R. N. Singaraju, N. Smirnov, R. Snellings, G. Sood, P. Sorensen, J. Sowinski, J. Speltz, H. M. Spinka, B. Srivastava, A. Stadnik, T. D. S. Stanislaus, R. Stock, A. Stolpovsky, M. Strikhanov, B. Stringfellow, A. A. P. Suaide, E. Sugarbaker, C. Suire, M. Sumbera, B. Surrow, M. Swanger, T. J. M. Symons, A. Szanto de Toledo, A. Tai, J. Takahashi, A. H. Tang, T. Tarnowsky, D. Thein, J. H. Thomas, S. Timoshenko, M. Tokarev, S. Trentalange, R. E. Tribble, O. D. Tsai, J. Ulery, T. Ullrich, D. G. Underwood, G. Van Buren, M. van Leeuwen, A. M. Vander Molen, R. Varma, I. M. Vasilevski, A. N. Vasiliev, R. Vernet, S. E. Vigdor, Y. P. Viyogi, S. Vokal, S. A. Voloshin, W. T. Waggoner, F. Wang, G. Wang, X. L. Wang, Y. Wang, Z. M. Wang, H. Ward, J. W. Watson, J. C. Webb, G. D. Westfall, A. Wetzler, C. Whitten Jr., H. Wieman, S. W. Wissink, R. Witt, J. Wood, J. Wu, N. Xu, Z. Xu, Z. Z. Xu, E. Yamamoto, P. Yepes, V. I. Yurevich, I. Zborovsky, H. Zhang, W. M. Zhang, Y. Zhang, Z. P. Zhang, R. Zoulkarneev, Y. Zoulkarneeva, A. N. Zubarev, Institut de Recherches Subatomiques (IReS), Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Cancéropôle du Grand Est-Université Louis Pasteur - Strasbourg I-Centre National de la Recherche Scientifique (CNRS), Laboratoire SUBATECH Nantes (SUBATECH), Mines Nantes (Mines Nantes)-Université de Nantes (UN)-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Centre National de la Recherche Scientifique (CNRS), STAR, and Centre National de la Recherche Scientifique (CNRS)-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Université de Nantes (UN)-Mines Nantes (Mines Nantes)

Subjects
Nuclear and High Energy Physics, Au Collisions, FOS: Physical sciences, nuclei with mass number 190 to 219, [PHYS.NEXP]Physics [physics]/Nuclear Experiment [nucl-ex], 01 natural sciences, 7. Clean energy, Nuclear physics, by-event fluctuations, heavy-ion collisions, quark-gluon plasma, transverse-momentum, au collisions, signatures, model, pp, Square root, 0103 physical sciences, Nuclear Experiment (nucl-ex), Multiplicity (chemistry), Nuclear Experiment, 010306 general physics, Transverse-Momentum, Physics, Large Hadron Collider, 010308 nuclear & particles physics, Signatures, Heavy-Ion Collisions, Pp, By-Event Fluctuations, Super Proton Synchrotron, Transverse plane, Thermalisation, 25.75.Gz, Quark–gluon plasma, Quark-Gluon Plasma, heavy ion-nucleus reactions, Physics::Accelerator Physics, Atomic physics, Relativistic Heavy Ion Collider, Model
Abstract

We present results for two-particle transverse momentum correlations, , as a function of event centrality for Au+Au collisions at sqrt(sNN) = 20, 62, 130, and 200 GeV at the Relativistic Heavy Ion Collider. We observe correlations decreasing with centrality that are similar at all four incident energies. The correlations multiplied by the multiplicity density increase with incident energy and the centrality dependence may show evidence of processes such as thermalization, minijet production, or the saturation of transverse flow. The square root of the correlations divided by the event-wise average transverse momentum per event shows little or no beam energy dependence and generally agrees with previous measurements at the Super Proton Synchrotron., Comment: 7 pages, 4 figures, RevTeX, final version as published in Physical Review C

Published
2005
Full Text
View/download PDF

2. Multistrange Baryon Elliptic Flow inAu+AuCollisions atsNN=200 GeV

Author

J. Adams, M. M. Aggarwal, Z. Ahammed, J. Amonett, B. D. Anderson, D. Arkhipkin, G. S. Averichev, S. K. Badyal, Y. Bai, J. Balewski, O. Barannikova, L. S. Barnby, J. Baudot, S. Bekele, V. V. Belaga, A. Bellingeri-Laurikainen, R. Bellwied, J. Berger, B. I. Bezverkhny, S. Bharadwaj, A. Bhasin, A. K. Bhati, V. S. Bhatia, H. Bichsel, J. Bielcik, J. Bielcikova, A. Billmeier, L. C. Bland, C. O. Blyth, S. L. Blyth, B. E. Bonner, M. Botje, A. Boucham, J. Bouchet, A. V. Brandin, A. Bravar, M. Bystersky, R. V. Cadman, X. Z. Cai, H. Caines, M. Calderón de la Barca Sánchez, J. Castillo, O. Catu, D. Cebra, Z. Chajecki, P. Chaloupka, S. Chattopadhyay, H. F. Chen, J. H. Chen, Y. Chen, J. Cheng, M. Cherney, A. Chikanian, W. Christie, J. P. Coffin, T. M. Cormier, M. R. Cosentino, J. G. Cramer, H. J. Crawford, D. Das, S. Das, M. Daugherity, M. M. de Moura, T. G. Dedovich, M. DePhillips, A. A. Derevschikov, L. Didenko, T. Dietel, S. M. Dogra, W. J. Dong, X. Dong, J. E. Draper, F. Du, A. K. Dubey, V. B. Dunin, J. C. Dunlop, M. R. Dutta Mazumdar, V. Eckardt, W. R. Edwards, L. G. Efimov, V. Emelianov, J. Engelage, G. Eppley, B. Erazmus, M. Estienne, P. Fachini, J. Faivre, R. Fatemi, J. Fedorisin, K. Filimonov, P. Filip, E. Finch, V. Fine, Y. Fisyak, K. S. F. Fornazier, J. Fu, C. A. Gagliardi, L. Gaillard, J. Gans, M. S. Ganti, F. Geurts, V. Ghazikhanian, P. Ghosh, J. E. Gonzalez, H. Gos, O. Grachov, O. Grebenyuk, D. Grosnick, S. M. Guertin, Y. Guo, A. Gupta, N. Gupta, T. D. Gutierrez, T. J. Hallman, A. Hamed, D. Hardtke, J. W. Harris, M. Heinz, T. W. Henry, S. Hepplemann, B. Hippolyte, A. Hirsch, E. Hjort, G. W. Hoffmann, M. J. Horner, H. Z. Huang, S. L. Huang, E. W. Hughes, T. J. Humanic, G. Igo, A. Ishihara, P. Jacobs, W. W. Jacobs, M. Jedynak, H. Jiang, P. G. Jones, E. G. Judd, S. Kabana, K. Kang, M. Kaplan, D. Keane, A. Kechechyan, V. Yu. Khodyrev, J. Kiryluk, A. Kisiel, E. M. Kislov, J. Klay, S. R. Klein, D. D. Koetke, T. Kollegger, M. Kopytine, L. Kotchenda, K. L. Kowalik, M. Kramer, P. Kravtsov, V. I. Kravtsov, K. Krueger, C. Kuhn, A. I. Kulikov, A. Kumar, R. Kh. Kutuev, A. A. Kuznetsov, M. A. C. Lamont, J. M. Landgraf, S. Lange, F. Laue, J. Lauret, A. Lebedev, R. Lednicky, S. Lehocka, M. J. LeVine, C. Li, Q. Li, Y. Li, G. Lin, S. J. Lindenbaum, M. A. Lisa, F. Liu, H. Liu, J. Liu, L. Liu, Q. J. Liu, Z. Liu, T. Ljubicic, W. J. Llope, H. Long, R. S. Longacre, M. Lopez-Noriega, W. A. Love, Y. Lu, T. Ludlam, D. Lynn, G. L. Ma, J. G. Ma, Y. G. Ma, D. Magestro, S. Mahajan, D. P. Mahapatra, R. Majka, L. K. Mangotra, R. Manweiler, S. Margetis, C. Markert, L. Martin, J. N. Marx, H. S. Matis, Yu. A. Matulenko, C. J. McClain, T. S. McShane, F. Meissner, Yu. Melnick, A. Meschanin, M. L. Miller, N. G. Minaev, C. Mironov, A. Mischke, D. K. Mishra, J. Mitchell, B. Mohanty, L. Molnar, C. F. Moore, D. A. Morozov, M. G. Munhoz, B. K. Nandi, S. K. Nayak, T. K. Nayak, J. M. Nelson, P. K. Netrakanti, V. A. Nikitin, L. V. Nogach, S. B. Nurushev, G. Odyniec, A. Ogawa, V. Okorokov, M. Oldenburg, D. Olson, S. K. Pal, Y. Panebratsev, S. Y. Panitkin, A. I. Pavlinov, T. Pawlak, T. Peitzmann, V. Perevoztchikov, C. Perkins, W. Peryt, V. A. Petrov, S. C. Phatak, R. Picha, M. Planinic, J. Pluta, N. Porile, J. Porter, A. M. Poskanzer, M. Potekhin, E. Potrebenikova, B. V. K. S. Potukuchi, D. Prindle, C. Pruneau, J. Putschke, G. Rakness, R. Raniwala, S. Raniwala, O. Ravel, R. L. Ray, S. V. Razin, D. Reichhold, J. G. Reid, J. Reinnarth, G. Renault, F. Retiere, A. Ridiger, H. G. Ritter, J. B. Roberts, O. V. Rogachevskiy, J. L. Romero, A. Rose, C. Roy, L. Ruan, M. Russcher, R. Sahoo, I. Sakrejda, S. Salur, J. Sandweiss, M. Sarsour, I. Savin, P. S. Sazhin, J. Schambach, R. P. Scharenberg, N. Schmitz, K. Schweda, J. Seger, P. Seyboth, E. Shahaliev, M. Shao, W. Shao, M. Sharma, W. Q. Shen, K. E. Shestermanov, S. S. Shimanskiy, E. Sichtermann, F. Simon, R. N. Singaraju, N. Smirnov, R. Snellings, G. Sood, P. Sorensen, J. Sowinski, J. Speltz, H. M. Spinka, B. Srivastava, A. Stadnik, T. D. S. Stanislaus, R. Stock, A. Stolpovsky, M. Strikhanov, B. Stringfellow, A. A. P. Suaide, E. Sugarbaker, C. Suire, M. Sumbera, B. Surrow, M. Swanger, T. J. M. Symons, A. Szanto de Toledo, A. Tai, J. Takahashi, A. H. Tang, T. Tarnowsky, D. Thein, J. H. Thomas, A. R. Timmins, S. Timoshenko, M. Tokarev, S. Trentalange, R. E. Tribble, O. D. Tsai, J. Ulery, T. Ullrich, D. G. Underwood, G. Van Buren, N. van der Kolk, M. van Leeuwen, A. M. Vander Molen, R. Varma, I. M. Vasilevski, A. N. Vasiliev, R. Vernet, S. E. Vigdor, Y. P. Viyogi, S. Vokal, S. A. Voloshin, W. T. Waggoner, F. Wang, G. Wang, X. L. Wang, Y. Wang, Z. M. Wang, H. Ward, J. W. Watson, J. C. Webb, G. D. Westfall, A. Wetzler, C. Whitten, H. Wieman, S. W. Wissink, R. Witt, J. Wood, J. Wu, N. Xu, Z. Xu, Z. Z. Xu, E. Yamamoto, P. Yepes, V. I. Yurevich, I. Zborovsky, H. Zhang, W. M. Zhang, Y. Zhang, Z. P. Zhang, C. Zhong, R. Zoulkarneev, Y. Zoulkarneeva, A. N. Zubarev, and J. X. Zuo

Subjects
Quark, Physics, Particle physics, 010308 nuclear & particles physics, Nuclear Theory, High Energy Physics::Phenomenology, Elliptic flow, Hadron, General Physics and Astronomy, Constituent quark, Parton, Strangeness, 01 natural sciences, Omega, Baryon, Nuclear physics, 0103 physical sciences, High Energy Physics::Experiment, Nuclear Experiment, 010306 general physics
Abstract

We report on the first measurement of elliptic flow $v_2(p_T)$ of multi-strange baryons $\Xi+\bar{Xi}$ and $\Omega+\bar{Omega} in heavy-ion collisions. In minimum bias Au+Au collisions at sqrt(s_NN) = 200 GeV, a significant amount of elliptic flow, comparable to other non-strange baryons, is observed for multi-strange baryons which are expected to be particularly sensitive to the dynamics of the partonic stage of heavy-ion collisions. The $p_T$ dependence of $v_2$ of the multi-strange baryons confirms the number of constituent quark scaling previously observed for lighter hadrons. These results support the idea that a substantial fraction of the observed collective motion is developed at the early partonic stage in ultra-relativistic nuclear collisions at RHIC.

Published
2005
Full Text
View/download PDF

3. Experimental and theoretical challenges in the search for the quark gluon plasma : The STAR collaboration's critical assessment of the evidence from RHIC collisions

Author

J. Adams, M.M. Aggarwal, Z. Ahammed, J. Amonett, B.D. Anderson, D. Arkhipkin, G.S. Averichev, S.K. Badyal, Y. Bai, J. Balewski, O. Barannikova, L.S. Barnby, J. Baudot, S. Bekele, V.V. Belaga, A. Bellingeri-Laurikainen, R. Bellwied, J. Berger, B.I. Bezverkhny, S. Bharadwaj, A. Bhasin, A.K. Bhati, V.S. Bhatia, H. Bichsel, J. Bielcik, J. Bielcikova, A. Billmeier, L.C. Bland, C.O. Blyth, B.E. Bonner, M. Botje, A. Boucham, J. Bouchet, A.V. Brandin, A. Bravar, M. Bystersky, R.V. Cadman, X.Z. Cai, H. Caines, M. Calderón de la Barca Sánchez, J. Castillo, O. Catu, D. Cebra, Z. Chajecki, P. Chaloupka, S. Chattopadhyay, H.F. Chen, Y. Chen, J. Cheng, M. Cherney, A. Chikanian, W. Christie, J.P. Coffin, T.M. Cormier, J.G. Cramer, H.J. Crawford, D. Das, S. Das, M.M. de Moura, T.G. Dedovich, A.A. Derevschikov, L. Didenko, T. Dietel, S.M. Dogra, W.J. Dong, X. Dong, J.E. Draper, F. Du, A.K. Dubey, V.B. Dunin, J.C. Dunlop, M.R. Dutta Mazumdar, V. Eckardt, W.R. Edwards, L.G. Efimov, V. Emelianov, J. Engelage, G. Eppley, B. Erazmus, M. Estienne, P. Fachini, J. Faivre, R. Fatemi, J. Fedorisin, K. Filimonov, P. Filip, E. Finch, V. Fine, Y. Fisyak, J. Fu, C.A. Gagliardi, L. Gaillard, J. Gans, M.S. Ganti, F. Geurts, V. Ghazikhanian, P. Ghosh, J.E. Gonzalez, H. Gos, O. Grachov, O. Grebenyuk, D. Grosnick, S.M. Guertin, Y. Guo, A. Gupta, T.D. Gutierrez, T.J. Hallman, A. Hamed, D. Hardtke, J.W. Harris, M. Heinz, T.W. Henry, S. Hepplemann, B. Hippolyte, A. Hirsch, E. Hjort, G.W. Hoffmann, H.Z. Huang, S.L. Huang, E.W. Hughes, T.J. Humanic, G. Igo, A. Ishihara, P. Jacobs, W.W. Jacobs, M. Jedynak, H. Jiang, P.G. Jones, E.G. Judd, S. Kabana, K. Kang, M. Kaplan, D. Keane, A. Kechechyan, V.Yu. Khodyrev, J. Kiryluk, A. Kisiel, E.M. Kislov, J. Klay, S.R. Klein, D.D. Koetke, T. Kollegger, M. Kopytine, L. Kotchenda, M. Kramer, P. Kravtsov, V.I. Kravtsov, K. Krueger, C. Kuhn, A.I. Kulikov, A. Kumar, R.Kh. Kutuev, A.A. Kuznetsov, M.A.C. Lamont, J.M. Landgraf, S. Lange, F. Laue, J. Lauret, A. Lebedev, R. Lednicky, S. Lehocka, M.J. LeVine, C. Li, Q. Li, Y. Li, G. Lin, S.J. Lindenbaum, M.A. Lisa, F. Liu, H. Liu, L. Liu, Q.J. Liu, Z. Liu, T. Ljubicic, W.J. Llope, H. Long, R.S. Longacre, M. Lopez-Noriega, W.A. Love, Y. Lu, T. Ludlam, D. Lynn, G.L. Ma, J.G. Ma, Y.G. Ma, D. Magestro, S. Mahajan, D.P. Mahapatra, R. Majka, L.K. Mangotra, R. Manweiler, S. Margetis, C. Markert, L. Martin, J.N. Marx, H.S. Matis, Yu.A. Matulenko, C.J. McClain, T.S. McShane, F. Meissner, Yu. Melnick, A. Meschanin, M.L. Miller, N.G. Minaev, C. Mironov, A. Mischke, D.K. Mishra, J. Mitchell, B. Mohanty, L. Molnar, C.F. Moore, D.A. Morozov, M.G. Munhoz, B.K. Nandi, S.K. Nayak, T.K. Nayak, J.M. Nelson, P.K. Netrakanti, V.A. Nikitin, L.V. Nogach, S.B. Nurushev, G. Odyniec, A. Ogawa, V. Okorokov, M. Oldenburg, D. Olson, S.K. Pal, Y. Panebratsev, S.Y. Panitkin, A.I. Pavlinov, T. Pawlak, T. Peitzmann, V. Perevoztchikov, C. Perkins, W. Peryt, V.A. Petrov, S.C. Phatak, R. Picha, M. Planinic, J. Pluta, N. Porile, J. Porter, A.M. Poskanzer, M. Potekhin, E. Potrebenikova, B.V.K.S. Potukuchi, D. Prindle, C. Pruneau, J. Putschke, G. Rakness, R. Raniwala, S. Raniwala, O. Ravel, R.L. Ray, S.V. Razin, D. Reichhold, J.G. Reid, J. Reinnarth, G. Renault, F. Retiere, A. Ridiger, H.G. Ritter, J.B. Roberts, O.V. Rogachevskiy, J.L. Romero, A. Rose, C. Roy, L. Ruan, M. Russcher, R. Sahoo, I. Sakrejda, S. Salur, J. Sandweiss, M. Sarsour, I. Savin, P.S. Sazhin, J. Schambach, R.P. Scharenberg, N. Schmitz, J. Seger, P. Seyboth, E. Shahaliev, M. Shao, W. Shao, M. Sharma, W.Q. Shen, K.E. Shestermanov, S.S. Shimanskiy, E. Sichtermann, F. Simon, R.N. Singaraju, N. Smirnov, R. Snellings, G. Sood, P. Sorensen, J. Sowinski, J. Speltz, H.M. Spinka, B. Srivastava, A. Stadnik, T.D.S. Stanislaus, R. Stock, A. Stolpovsky, M. Strikhanov, B. Stringfellow, A.A.P. Suaide, E. Sugarbaker, C. Suire, M. Sumbera, B. Surrow, M. Swanger, T.J.M. Symons, A. Szanto de Toledo, A. Tai, J. Takahashi, A.H. Tang, T. Tarnowsky, D. Thein, J.H. Thomas, S. Timoshenko, M. Tokarev, S. Trentalange, R.E. Tribble, O.D. Tsai, J. Ulery, T. Ullrich, D.G. Underwood, G. Van Buren, M. van Leeuwen, A.M. Vander Molen, R. Varma, I.M. Vasilevski, A.N. Vasiliev, R. Vernet, S.E. Vigdor, Y.P. Viyogi, S. Vokal, S.A. Voloshin, W.T. Waggoner, F. Wang, G. Wang, X.L. Wang, Y. Wang, Z.M. Wang, H. Ward, J.W. Watson, J.C. Webb, G.D. Westfall, A. Wetzler, C. Whitten, H. Wieman, S.W. Wissink, R. Witt, J. Wood, J. Wu, N. Xu, Z. Xu, Z.Z. Xu, E. Yamamoto, P. Yepes, V.I. Yurevich, I. Zborovsky, H. Zhang, W.M. Zhang, Y. Zhang, Z.P. Zhang, R. Zoulkarneev, Y. Zoulkarneeva, A.N. Zubarev, Institut de Recherches Subatomiques (IReS), Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Cancéropôle du Grand Est-Université Louis Pasteur - Strasbourg I-Centre National de la Recherche Scientifique (CNRS), Laboratoire SUBATECH Nantes (SUBATECH), Centre National de la Recherche Scientifique (CNRS)-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Université de Nantes (UN)-Mines Nantes (Mines Nantes), STAR, and Mines Nantes (Mines Nantes)-Université de Nantes (UN)-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Centre National de la Recherche Scientifique (CNRS)

Subjects
Physics, Quantum chromodynamics, Nuclear and High Energy Physics, Particle physics, 010308 nuclear & particles physics, Elliptic flow, Lattice field theory, 25.75.-q, Strangeness production, FOS: Physical sciences, Lattice QCD, [PHYS.NEXP]Physics [physics]/Nuclear Experiment [nucl-ex], 01 natural sciences, Nuclear physics, Strange matter, 0103 physical sciences, Quark–gluon plasma, Nuclear Experiment (nucl-ex), 010306 general physics, Jet quenching, Nuclear Experiment
Abstract

We review the most important experimental results from the first three years of nucleus-nucleus collision studies at RHIC, with emphasis on results from the STAR experiment, and we assess their interpretation and comparison to theory. The theory-experiment comparison suggests that central Au+Au collisions at RHIC produce dense, rapidly thermalizing matter characterized by: (1) initial energy densities above the critical values predicted by lattice QCD for establishment of a Quark-Gluon Plasma (QGP); (2) nearly ideal fluid flow, marked by constituent interactions of very short mean free path, established most probably at a stage preceding hadron formation; and (3) opacity to jets. Many of the observations are consistent with models incorporating QGP formation in the early collision stages, and have not found ready explanation in a hadronic framework. However, the measurements themselves do not yet establish unequivocal evidence for a transition to this new form of matter. The theoretical treatment of the collision evolution, despite impressive successes, invokes a suite of distinct models, degrees of freedom and assumptions of as yet unknown quantitative consequence. We pose a set of important open questions, and suggest additional measurements, at least some of which should be addressed in order to establish a compelling basis to conclude definitively that thermalized, deconfined quark-gluon matter has been produced at RHIC., Comment: 101 pages, 37 figures; revised version to Nucl. Phys. A

Published
2005
Full Text
View/download PDF

4. Three Prospective Case Studies Examining Mifepristone's Efficacy in Patients with Treatment-Resistant PTSD.

Author

van Minnen A, Vos L, Bet PM, de Jongh A, Linsen F, van Marle HJF, Meijer OC, Otte WM, Russcher M, and Vinkers CH

Abstract

Despite the availability of various treatment approaches for patients with posttraumatic stress disorder (PTSD), some patients do not respond to these therapies, and novel treatment approaches are needed. This study investigated the efficacy of mifepristone, a glucocorticoid receptor antagonist, in treatment-resistant PTSD patients. Three patients with PTSD who were resistant to standard psychological and pharmacological treatments were prescribed mifepristone (600-1,200 mg/day) for 1 week. A baseline-controlled single-case design was used, involving a 2-week baseline phase (no intervention), a 1-week intervention phase (mifepristone), and a 2-week postintervention phase. The primary outcome measure, self-reported PTSD symptom severity (PCL-5), was assessed daily, with participants providing their own control condition. Two of the three patients experienced a significant reduction in PTSD symptom severity after the intervention phase and no longer met the diagnostic criteria for PTSD. These positive results were maintained during long-term follow-up. These findings support the potential effectiveness of mifepristone in the treatment of patients with treatment-resistant PTSD. However, our findings must be interpreted with caution, and further studies with larger sample sizes and more rigorous designs are necessary to confirm the promising results., Competing Interests: The authors declare that they have no conflicts of interest., (Copyright © 2024 Agnes van Minnen et al.)

Published
2024
Full Text
View/download PDF

5. The effects of kidney transplantation on sleep, melatonin, circadian rhythm and quality of life in kidney transplant recipients and living donors.

Author

Russcher M, Nagtegaal JE, Nurmohamed SA, Koch BC, van der Westerlaken MM, van Someren EJ, Bakker SJ, Ter Wee PM, and Gaillard CA

Subjects
Adult, Aged, Blood Pressure, Body Temperature, Female, Humans, Kidney Failure, Chronic complications, Kidney Failure, Chronic physiopathology, Kidney Failure, Chronic surgery, Longitudinal Studies, Male, Middle Aged, Prospective Studies, Quality of Life, Saliva metabolism, Sleep Disorders, Circadian Rhythm etiology, Transplant Recipients, Wakefulness, Circadian Rhythm, Kidney Transplantation, Living Donors, Melatonin metabolism, Sleep
Abstract

Background: Sleep disturbance is an important medical problem in patients with end-stage renal disease. It might be related to the disruption of the body's circadian clock since nocturnal levels of its key biomarker melatonin are markedly reduced. We aimed at investigating whether a change in renal function due to kidney transplantation or donation would modify sleep, melatonin levels, circadian rhythmicity, and quality of life in kidney transplant recipients (KTR) and living donors (LD)., Methods: In KTR, we assessed saliva melatonin concentrations, sleep quality and daytime sleepiness prior to and at 2 weeks and 3 months after transplantation. In LD, we assessed these parameters prior to and at 3 months after donation. We additionally assessed 24-hour core body temperature (cBT), 24-hour blood pressure profile, and quality of life (QoL) prior to and 3 months after transplantation., Results: Twenty-three KTR and 23 LD completed the study. Regarding sleep, the amount of nighttime awake minutes tended to be reduced in recipients after transplantation (p = 0.05). Nocturnal melatonin concentrations did not change with transplantation or donation. Blood pressure dipping profile and the two circadian markers dim-light melatonin onset and time of core body temperature minimum did not change. Nevertheless, KTR reported that daytime sleepiness and QoL had improved., Conclusion: Objectively nocturnal sleep quality marginally improved after transplantation. Subjectively patients reported improved QoL and daytime sleepiness scores. Changes in renal function were not associated with modified melatonin secretion or circadian rhythmicity.

Published
2015
Full Text
View/download PDF

6. An observational study on disturbed peripheral circadian rhythms in hemodialysis patients.

Author

Russcher M, Chaves I, Lech K, Koch BC, Nagtegaal JE, Dorsman KF, Jong A', Kayser M, van Faassen HM, Kema IP, van der Horst GT, and Gaillard CA

Subjects
Aged, Biomarkers blood, Cell Line, Fatigue complications, Fatigue diagnosis, Female, Gene Expression Profiling, Humans, Hydrocortisone blood, Kidney Failure, Chronic therapy, Male, Melatonin blood, Middle Aged, Prospective Studies, Sleep, Surveys and Questionnaires, Circadian Rhythm, Kidney Failure, Chronic complications, Quality of Life, Renal Dialysis adverse effects, Sleep Disorders, Circadian Rhythm complications, Sleep Disorders, Circadian Rhythm diagnosis
Abstract

The quality of life of hemodialysis (HD) patients is hampered by reduced nocturnal sleep quality and excessive daytime sleepiness. In addition to the sleep/wake cycle, levels of circadian biomarkers (e.g. melatonin) are disturbed in end-stage renal disease (ESRD). This suggests impaired circadian clock performance in HD patients, but the underlying mechanism is unknown. In this observational study, diurnal rhythms of sleep, serum melatonin and cortisol concentrations and clock gene mRNA expression are compared between HD patients (n = 9) and healthy control subjects (n = 9). In addition, the presence of circulating factors that might affect circadian rhythmicity is tested in vitro with cell culture experiments. Reduced sleep quality (median sleep onset latency [interquartile range] of 23.9 [17.3] min for patients versus 5.0 [10] minutes for controls, p < 0.01; mean (± SD) sleep efficiency 70.2 ± 8.1% versus 82.9 ± 10.9%, p = 0.02 and mean awake minutes after sleep onset 104.8 ± 27.9 versus 54.6 ± 41.6 minutes, p =  0.01) and increased daytime sleepiness (mean Epworth Sleepiness Score of 10.0 ± 4.8 versus 3.9 ± 2.0, p < 0.01) were confirmed in HD patients. Reduced nocturnal melatonin concentrations (1 AM: 98.1 [122.9] pmol/L versus 12.5 [44.2] pmol/L, p =  0.019; 5 AM: 114.0 [131.6] pmol/L versus 11.8 [86.8] pmol/L, p =  0.031) and affected circadian control of cortisol rhythm and circadian expression of the clock gene REV-ERBα were found. HD patient serum had a higher capacity to synchronize cells in vitro, suggesting an accumulated level of clock resetting compounds in HD patients. These compounds were not cleared by hemodialysis treatment or related to frequently used medications. In conclusion, the abovementioned results strongly suggest a disturbance in circadian timekeeping in peripheral tissues of HD patients. Accumulation of clock resetting compounds possibly contributes to this. Future studies are needed for a better mechanistic understanding of the interaction between renal failure and perturbation of the circadian clock.

Published
2015
Full Text
View/download PDF

7. Long-term effects of melatonin on quality of life and sleep in haemodialysis patients (Melody study): a randomized controlled trial.

Author

Russcher M, Koch BC, Nagtegaal JE, van Ittersum FJ, Pasker-de Jong PC, Hagen EC, van Dorp WT, Gabreëls B, Wildbergh TX, van der Westerlaken MM, Gaillard CA, and Ter Wee PM

Subjects
Actigraphy, Aged, Antioxidants administration & dosage, Antioxidants therapeutic use, Dietary Supplements, Double-Blind Method, Female, Follow-Up Studies, Humans, Male, Melatonin administration & dosage, Middle Aged, Saliva chemistry, Sleep drug effects, Sleep Disorders, Circadian Rhythm etiology, Time Factors, Melatonin therapeutic use, Quality of Life, Renal Dialysis, Sleep Disorders, Circadian Rhythm drug therapy
Abstract

Aim: The disturbed circadian rhythm in haemodialysis patients results in perturbed sleep. Short term melatonin supplementation has alleviated these sleep problems. Our aim was to investigate the effects of long-term melatonin supplementation on quality of life and sleep., Methods: In this randomized double-blind placebo-controlled trial haemodialysis patients suffering from subjective sleep problems received melatonin 3 mg day(-1) vs. placebo during 12 months. The primary endpoint quality of life parameter 'vitality' was measured with Medical Outcomes Study Short Form-36. Secondary outcomes were improvement of three sleep parameters measured by actigraphy and nighttime salivary melatonin concentrations., Results: Sixty-seven patients were randomized. Forty-two patients completed the trial. With melatonin, no beneficial effect on vitality was seen. Other quality of life parameters showed both advantageous and disadvantageous effects of melatonin. Considering sleep, at 3 months sleep efficiency and actual sleep time had improved with melatonin compared with placebo on haemodialysis days (difference 7.6%, 95% CI 0.77, 14.4 and 49 min, 95% CI 2.1, 95.9, respectively). At 12 months none of the sleep parameters differed significantly from placebo. Melatonin salivary concentrations at 6 months had significantly increased in the melatonin group compared with the placebo group., Conclusions: The high drop-out rate limits the strength of our conclusions. However, although a previous study reported beneficial short term effects of melatonin on sleep in haemodialysis patients, in this long-term study the positive effects disappeared during follow up (6-12 months). Also the quality of life parameter, vitality, did not improve. Efforts should be made to elucidate the mechanism responsible for the loss of effect with chronic use., (© 2013 The Authors. British Journal of Clinical Pharmacology © 2013 The British Pharmacological Society.)

Published
2013
Full Text
View/download PDF

8. Preemptive dosage reduction of nadroparin in patients with renal failure: a retrospective case series.

Author

Russcher M, Josephus Jitta N, Kraaijenhagen RJ, Fijnheer R, Pasker-de Jong PC, and Gaillard CA

Abstract

Background: Low-molecular-weight heparins (LMWHs) are frequently used to treat arterial and venous thrombo-embolic events. LMWHs accumulate with renal failure, but only limited clinical data regarding appropriate dosage adjustments are available. Nevertheless, LMWHs are routinely used in these patients worldwide. Although many clinics apply renal function-based dosage reductions, anti-factor Xa (anti-Xa) activity is not measured routinely., Methods: We determined anti-Xa activity in 51 patients with MDRD-eGFR <60 mL/min/1.73 m(2), treated with therapeutic doses of nadroparin according to a standard, renal function-based guideline., Results: An a priori dosage reduction resulted in anti-Xa activity within, below and above the reference range in 51, 30 and 19% of the measurements, respectively. Treatment resulted in different anti-Xa activities compared with dosages that were not given according to official advice (P < 0.001). Anti-Xa values increased with longer treatment duration (P = 0.038)., Conclusions: A preemptive fixed reduction (25%) of the nadroparin dosage in all patients with renal failure seems appropriate. However, because target anti-Xa activities were reached in only half of the patients, we submit that the use of nadroparin, dosage reduction and monitoring of anti-Xa activity in combination with clinical outcome monitoring in this patient population urgently needs further investigation.

Published
2013
Full Text
View/download PDF

9. The role of melatonin treatment in chronic kidney disease.

Author

Russcher M, Koch B, Nagtegaal E, van der Putten K, ter Wee P, and Gaillard C

Subjects
Blood Pressure drug effects, Chronobiology Disorders drug therapy, Chronobiology Disorders etiology, Chronobiology Disorders physiopathology, Chronotherapy, Humans, Inflammation Mediators physiology, Kidney Failure, Chronic drug therapy, Kidney Failure, Chronic physiopathology, Kidney Failure, Chronic psychology, Melatonin physiology, Models, Biological, Oxidative Stress drug effects, Renal Dialysis adverse effects, Renal Insufficiency, Chronic physiopathology, Renal Insufficiency, Chronic psychology, Sleep Wake Disorders drug therapy, Sleep Wake Disorders etiology, Sleep Wake Disorders physiopathology, Stress, Psychological, Melatonin therapeutic use, Renal Insufficiency, Chronic drug therapy
Abstract

The pineal hormone melatonin plays a major role in circadian sleep-wake rhythm. Patients with Chronic Kidney Disease (CKD), especially those who are on hemodialysis, frequently suffer from sleep disturbances. In this review an overview is given of the classification of stages of chronic kidney disease, followed by a presentation of the circadian rhythm disorders in renal disease involving sleep disturbances in relation to melatonin deficiency. The therapeutic benefit of melatonin treatment in sleep disorders related to chronic kidney disease including the controlled trials solving this topic, is described. Furthermore, the beneficial effect of melatonin on blood pressure alterations in CKD states and the protection of melatonin in oxidative stress and inflammation in renal disorders are explored. Finally a hypothetic model is described for the relation between circadian rhythm disorders and CKD.

Published
2012
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results